SNY 📈 Sanofi ADR - Overview

Exchange: NASDAQ • Country: France • Currency: USD • Type: Common Stock • ISIN: US80105N1054

SNY: Vaccines, Medicines, Skincare, Diabetes, Oncology, Cardiovascular

Sanofi, a leading healthcare company, is dedicated to improving lives through innovative therapeutic solutions. With a strong presence in the United States, Europe, Canada, and internationally, the company operates through three main segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.

In the Pharmaceuticals segment, Sanofi focuses on developing and marketing specialty care products, including DUPIXENT for atopic dermatitis, as well as treatments for neurology and immunology, rare diseases, oncology, and rare blood disorders. The company also offers medicines for diabetes and cardiovascular diseases, along with established prescription products.

Through its Vaccines segment, Sanofi provides a range of vaccines to protect against various diseases, including poliomyelitis, pertussis, and hib pediatric vaccines, as well as influenza, booster, meningitis, and travel and endemic vaccines. These vaccines include protection against hepatitis A, typhoid, cholera, yellow fever, and rabies.

In the Consumer Healthcare segment, Sanofi offers a variety of over-the-counter (OTC) products, including cough, cold, and flu remedies, allergy medications, and pain relief products. The company also provides physical, mental, and digestive wellness products, as well as skincare solutions for itching, hydration, aging, cracking, and specialty skincare needs like eczema.

Sanofi is committed to advancing healthcare through strategic collaborations and partnerships. The company has agreements with Exscientia to develop novel small-molecule therapies for oncology and immunology, and with ABL Bio, Inc. to develop a treatment for alpha-synucleinopathies. Additionally, Sanofi has partnerships with Blackstone Life Sciences, Seagen Inc., IGM Biosciences, Inc., Skyhawk Therapeutics, Inc, Adagene Inc., Scribe Therapeutics Inc., and Provention Bio, Inc. to develop and commercialize innovative treatments.

With a rich history dating back to 1994, Sanofi was formerly known as Sanofi-Aventis before changing its name in May 2011. Headquartered in Paris, France, the company continues to drive innovation and improve healthcare outcomes worldwide. For more information, visit https://www.sanofi.com.

Additional Sources for SNY Stock

SNY Stock Overview

Market Cap in USD 125,010m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Industry Pharmaceuticals
TER 0.00%
IPO / Inception 2002-07-01

SNY Stock Ratings

Growth 5y 38.2%
Fundamental 58.6%
Dividend 58.0%
Rel. Performance Sector -0.98
Analysts 4.5/5
Fair Price Momentum 43.51 USD
Fair Price DCF 42.13 USD

SNY Dividends

Dividend Yield 12m 4.23%
Yield on Cost 5y 5.14%
Annual Growth 5y 1.82%
Payout Consistency 97.05%

SNY Growth Ratios

Growth Correlation 3m -96.1%
Growth Correlation 12m 53.9%
Growth Correlation 5y 65.2%
CAGR 5y 3.99%
CAGR/Mean DD 5y 0.46
Sharpe Ratio 12m 0.08
Alpha -17.29
Beta 0.57
Volatility 20.44%
Current Volume 2555.1k
Average Volume 20d 2379.2k
What is the price of SNY stocks?
As of December 04, 2024, the stock is trading at USD 48.17 with a total of 2,555,140 shares traded.
Over the past week, the price has changed by -0.23%, over one month by -9.03%, over three months by -16.27% and over the past year by +2.45%.
Is Sanofi ADR a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Sanofi ADR (NASDAQ:SNY) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 58.61 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SNY as of December 2024 is 43.51. This means that SNY is currently overvalued and has a potential downside of -9.67%.
Is SNY a buy, sell or hold?
Sanofi ADR has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy SNY.
  • Strong Buy: 5
  • Buy: 2
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for SNY stock price target?
According to ValueRays Forecast Model, SNY Sanofi ADR will be worth about 47.5 in December 2025. The stock is currently trading at 48.17. This means that the stock has a potential downside of -1.47%.
Issuer Forecast Upside
Wallstreet Target Price 63.5 31.8%
Analysts Target Price 65.1 35.2%
ValueRay Target Price 47.5 -1.5%